The estimated Net Worth of Bruce L A Carter is at least 2.01 百万$ dollars as of 12 August 2022. Bruce Carter owns over 10,000 units of Mirati Therapeutics Inc stock worth over 940,433$ and over the last 12 years he sold MRTX stock worth over 464,252$. In addition, he makes 606,671$ as Independent Director at Mirati Therapeutics Inc.
Bruce has made over 19 trades of the Mirati Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of MRTX stock worth 270,000$ on 12 August 2022.
The largest trade he's ever made was exercising 76,744 units of Mirati Therapeutics Inc stock on 24 May 2017 worth over 45,279$. On average, Bruce trades about 3,946 units every 56 days since 2012. As of 12 August 2022 he still owns at least 16,021 units of Mirati Therapeutics Inc stock.
You can see the complete history of Bruce Carter stock trades at the bottom of the page.
Dr. Bruce L. A. Carter Ph.D. serves as Independent Director of the Company. Dr. Carter has served as a member of our Board of Directors since September 2016. Dr. Carter currently serves as a director of Dr. Reddy’s Laboratories Limited and Enanta Pharmaceuticals, Inc. Dr. Carter is an affiliate Professor in the Department of Biotechnology at the University of Washington, Seattle Washington, a position he has held since 1986. Dr. Carter served on the Board of Xencor, Inc. from 2009 to 2017. Dr. Carter served on the board for QLT, Inc. from 2006 to 2012. Dr. Carter served as Executive Chairman of Immune Design Corp. a privately-held biotechnology company from 2009 to 2011, and he served as a director from 2009 to 2012. From 1998 to 2009, Dr. Carter served as President and Chief Executive Officer of ZymoGenetics, Inc., a publicly-held biotechnology company, and as its Chairman of the Board from 2005 until it was acquired by Bristol-Myers Squibb in October 2010. From 1994 to 1998 Dr. Carter was the Chief Scientific Officer of Novo Nordisk, a publicly-held pharmaceutical company. Previously, he held positions in research at Zymogenetics and G.D. Searle & Co. Ltd. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.
As the Independent Director of Mirati Therapeutics Inc, the total compensation of Bruce Carter at Mirati Therapeutics Inc is 606,671$. There are 7 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of 8,484,390$.
Bruce Carter is 76, he's been the Independent Director of Mirati Therapeutics Inc since 2016. There are no older and 19 younger executives at Mirati Therapeutics Inc.
Bruce's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over 179,669,845$ worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth 186,410,608$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Capital Advisors Llc Aghaza...、Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of 5,885,145$. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth 94,255$.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: